title: Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease--a randomized, multicenter, double-blind, placebo-controlled study.
abstract: BACKGROUND
  Indacaterol is a long-acting beta-2 agonist for once-daily treatment of COPD. We evaluated the effects of indacaterol 150 μg on lung hyperinflation compared with placebo and open-label tiotropium 18 μg. We measured physical activity during treatment with indacaterol 150 μg and matched placebo.
  
  
  METHODS
  We performed a randomized, three-period, cross-over study (21 days of treatment separated by two wash-out periods of 13 days) with indacaterol 150 μg or matching placebo and tiotropium 18 μg. Lung function was assessed by body plethysmography and spirometry. Physical activity was measured for one week by a multisensory armband at the end of both treatment periods with indacaterol/matched placebo. The primary endpoint was peak inspiratory capacity at the end of each treatment period.
  
  
  RESULTS
  129 patients (mean age, 61 years; mean post-bronchodilator FEV1, 64%), were randomized and 110 patients completed the study. Peak inspiratory capacity was 0.22 L greater with Indacaterol at day 21 compared to placebo (p < 0.001). Similar results were observed for tiotropium. Both bronchodilators also significantly improved other parameters of lung hyperinflation compared with placebo. All parameters of physical activity were significantly increased during treatment with indacaterol versus placebo.
  
  
  CONCLUSIONS
  Indacaterol 150 μg improved lung hyperinflation in patients with moderate COPD, which was associated with an increase of physical activity.
  
  
  BACKGROUND
  ClinicalTrials.gov registration number: NCT01012765.
authors.affiliation: Pulmonary Research Institute at LungClinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research, Woehrendamm 80, D-22927 Grosshansdorf, Germany. h.watz@pulmoresearch.de.
authors.forename: Henrik
authors.initials: H
authors.lastname: Watz
authors.forename: Felix
authors.initials: F
authors.lastname: Krippner
authors.forename: Anne
authors.initials: A
authors.lastname: Kirsten
authors.forename: Helgo
authors.initials: H
authors.lastname: Magnussen
authors.forename: Claus
authors.initials: C
authors.lastname: Vogelmeier
mesh_terms: D056044:Actigraphy; D000368:Aged; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D007189:Indans / Q000009:adverse effects / Q000627:therapeutic use*; D007320:Inspiratory Capacity / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects*; D010992:Plethysmography, Impedance; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use*; D012602:Scopolamine Derivatives / Q000627:therapeutic use; D013147:Spirometry; D000069447:Tiotropium Bromide
chemical_list: D001993:Bronchodilator Agents; D007189:Indans; D015363:Quinolones; D012602:Scopolamine Derivatives; C510790:indacaterol; D000069447:Tiotropium Bromide